• Atox Bio Ltd., of Ness Ziona, Israel, reported top-line results from a Phase IIa trial showing that AB103, a short peptide immune regulatory therapy, produced meaningful improvement across multiple endpoints vs. placebo in patients with necrotizing soft-tissue infections.